NCT00804830

Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer

Phase 2 Study With Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Region Skane · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Anaplastic Thyroid Cancer is a very aggressive disease. The investigators believe that angiogenesis is very important for these tumors to progress. Preclinical data is suggesting this. This is why we we prospectively want to treat these patients with avastin (and doxorubicin). However, local control is of major concern. Therefore, patients are initially treated with hyperfractionated radiotherapy and undergo surgery. Then they can enter this study.

Detailed description

Patients with Anaplastic Thyroid Cancer have a poor prognosis. We will treat the patients initially with our standard radiochemotherapy, which consists of doxorubicin 20mg fixed dose/week and hyperfractionated radiotherapy 1,6 Gy twice daily up to 46 Gy in total. The first week during radiotherapy, they will also receive Avastin 15mg/kg. 1-2 weeks after radiotherapy patients will undergo surgery of their primary tumor. After this "standard" therapy patients can be included in this study. Treatment is 20 mg fixed dose doxorubicin q1w and avastin 15mg/kg q3w. Treatment will continue maximum 6 months or until progress or until intolerable side effects occur.

Conditions

• Thyroid Neoplasms
• Carcinoma
• Thyroid Cancer
• Metastatic Cancer

Interventions

Type	Name	Description
DRUG	Bevacizumab	Avastin 15 mg/kg q3w and doxorubicin 20 mg q1w

Timeline

• Start date: 2008-04-01
• Primary completion: 2012-12-01
• Completion: 2014-12-01
• First posted: 2008-12-09
• Last updated: 2018-08-28

Locations

3 sites across 1 country: Sweden